ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II cl…
Biotechnology
US, Winston-Salem [HQ]
PROK/Financial Reporting
Income Statements
5 Sheets · Starting from 2019In Million USD. Margins, Growth Rates In %
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Revenue | - - | - - | - - | - - | - - | |
|
EPS
|
-1.01 | -0.14 | -0.30 | -2.41 | -0.57 | |
| Diluted in mil. | -1.01 | -0.14 | -0.30 | -2.41 | -0.57 | |
|
Profit
|
- - | - - | -1.00 | -3.00 | -3.00 | |
| Gross Margin | - - | - - | - - | - - | - - | |
| Pre Tax | -79.00 | -26.00 | -55.00 | -147.00 | -129.00 | |
| Profit Margin | - - | - - | - - | - - | - - | |
| ETR | -0.46 | 0.86 | -0.07 | -0.61 | -4.63 | |
| Net | -79.00 | -26.00 | -55.00 | -148.00 | -35.00 | |
| Profit Margin | - - | - - | - - | - - | - - | |
| EBITDA | -18.00 | -26.00 | -53.00 | -143.00 | -148.00 | |
| EBITDA Margin | - - | - - | - - | - - | - - | |
| Operating Income | -19.00 | -27.00 | -55.00 | -153.00 | -151.00 | |
| Operating Margin | - - | - - | - - | - - | - - | |
| Interest Income | - - | - - | - - | 5.00 | 22.00 | |
| Loss | -79.00 | -27.00 | -55.00 | -153.00 | -151.00 | |
| Cost of Revenue | - - | - - | -1.00 | -3.00 | -3.00 | |
|
Operating Expenses
|
-79.00 | -27.00 | -55.00 | -153.00 | -148.00 | |
| R&D | -75.00 | -21.00 | -46.00 | -82.00 | -106.00 | |
| G&A | -4.00 | -5.00 | -8.00 | -70.00 | -43.00 | |
| SG&A | -4.00 | -5.00 | -8.00 | -70.00 | -41.00 | |
| S&M | - - | - - | - - | - - | -3.00 | |
| Depreciation and Amortization | - - | - - | -1.00 | -3.00 | -3.00 | |
| Interest Expenses | - - | - - | - - | - - | - - | |
| Other Expenses | -60.00 | - - | - - | -5.00 | -22.00 | |
|
WA Shares Outstanding
|
78.00 | 186.00 | 186.00 | 61.00 | 61.00 | |
| Diluted | 78.00 | 186.00 | 186.00 | 61.00 | 61.00 |